Where targeted therapeutics fail, DNA Stars will cure disease
Existing Antibody Drug Conjugates, Bispecific Antibodies, and CAR-T cell therapies result in high relapse rates
Many targeted therapies are not able to seek and destroy the total heterogeneity of the disease. Chemo-resistant and biomarker-null stem cells, antibiotic resistant bacteria will cause the survival of individual pathogens.
Our precision therapy offers tunable multivalency to prevent residual disease with low “on target, off tumor” toxicity
Our multivalent therapeutics prevent the escape of individual cells and pathogens, eradicating the disease, improving patient outcomes, and shortening individual and societal disease burden, all with greatly reduced toxicity to normal cells
Modularity gives us the edge, allowing us unprecedented speed in custom drug development
Similar targeted therapeutics rely on antibodies and engineered receptors – targeting formats that require years of design, development, and investigation. Our therapeutics are fast to design – less than one day – quick to prove, and easily pushed into cells, animals, and humans.
Unlike other therapeutic developers, we can create biologics at the pace of nature.
Accelerate your drug discovery program by 10X
Let’s get started on fast track your drug development